[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623859":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":42,"collaborators":20,"id":46,"slug":20,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Additional imaging","EXPERIMENTAL","Additional CBCT scans will be made after each fraction, follow-up will be done using photon counting CT",[13],"Radiation: Additional radiation due to imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Additional radiation due to imaging","Additional imaging will be done using CT, therefore the patient will receive additional radiation dose",[9],null,[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Erasmus MC","RECRUITING","Rotterdam","South Holland","3000CA","Netherlands","NL",{"type":31,"coordinates":32},"Point",[33,34],4.47917,51.9225,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Department of radiotherapy","CONTACT","010-7041013","algemeen.secr.rt@erasmusmc.nl",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","E. (Euphemia) A.M. Froklage","Radiation Oncologist, MD PhD, principal investigator","100623859",false,"NCT07402109","CBCT Guided Markerless SBRT for Renal Cell Cancer","Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors","CT-STARRS","Inclusion Criteria:\n\n* Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence\n* No metastatic lesions\n* Patients must be 18 years or older\n* Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.\n\nWritten informed consent\n\nExclusion Criteria:\n\n* Previous high-dose radiotherapy in the region of the kidney","ALL","18 Years",{"count":56,"type":57},40,"ESTIMATED","INTERVENTIONAL",[60],"NA","This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques",[63],"Renal Cell Carcinoma (RCC)","2026-04-03",{"date":66,"type":67},"2026-04-08","ACTUAL",{"date":69,"type":67},"2026-04-01",{"date":71,"type":57},"2030-01-01",{"name":5,"class":6},1]